Sensei Biotherapeutics, Inc.
SNSE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | $2 | $1 |
| Gross Profit | -$1 | -$1 | -$2 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $19 | $18 | $30 | $22 |
| G&A Expenses | $0 | $19 | $0 | $0 |
| SG&A Expenses | $12 | $19 | $18 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1 | $0 | $0 |
| Operating Expenses | $31 | $36 | $47 | $37 |
| Operating Income | -$32 | -$37 | -$49 | -$37 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $3 | $1 | $1 |
| Pre-Tax Income | -$30 | -$34 | -$49 | -$37 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30 | -$34 | -$49 | -$37 |
| % Margin | – | – | – | – |
| EPS | -1.2 | -1.22 | -1.58 | -1.33 |
| % Growth | 1.6% | 22.8% | -18.8% | – |
| EPS Diluted | -1.2 | -1.22 | -1.58 | -1.33 |
| Weighted Avg Shares Out | 25 | 28 | 31 | 28 |
| Weighted Avg Shares Out Dil | 25 | 28 | 31 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $4 | $2 | $1 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $1 | $4 | $2 | $1 |
| EBITDA | -$30 | -$33 | -$47 | -$35 |
| % Margin | – | – | – | – |